secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-170701
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics prices $150M registered offering; net proceeds ~$144.7M
-------------------------------------------------------------------------

- Offering of 5,540,000 shares at $23.50/share and 850,000 pre-funded warrants at $23.499 each.
- Net proceeds of ~$144.7M to fund R&D for MZE829 (AMKD) and MZE782 (PKU, CKD) and general corporate purposes.
- Expected to close April 23, 2026; Leerink Partners LLC is sole underwriter.
- Participants include Farallon, T. Rowe Price, Frazier Life Sciences, Janus Henderson, and others.
- Cash runway extended into 2029 based on current business plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526170701/0001193125-26-170701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526170701/d115741d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-170701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer